Avacta and Adeptrix Collaborate to Develop Coronavirus Antigen Test Using Mass Spectrometry

Adeptrix’s novel BAMS platform combines enrichment of the sample to improve sensitivity with the power of mass-spectrometry to improve specificity. Hundreds of samples per day can be analysed by a single technician using BAMS, exceeding the capacity of single PCR machine, making BAMS a very attractive high throughput technique for COVID-19 screening in the clinical setting. Avacta’s recently developed Affimer reagents that bind the SARS-COV-2 spike protein will be used to provide the capture and enrichment of the virus particle from the sample which could be saliva, nasopharyngeal swabs or serum.

The diagnostic test will allow hospitals around the world to utilize their existing installed base of mass spectrometers that are not currently used for COVID-19 testing, thus contributing significantly to the increase in global testing capacity. The development of a BAMS test capable of diagnosing whether a person has the COVID-19 infection at any specific moment is a quick process and the companies are aiming to have a BAMS test ready for clinical validation, regulatory approval and manufacturing in June. Adeptrix and Avacta are already in discussion with large-scale manufacturing partners to rapidly deploy the new high throughput test.

“We are delighted to have established this partnership with Adeptrix in our push to develop Affimer -based COVID-19 antigen tests. Jeff and his team are world-renowned in the mass spectrometry field, and the BAMS diagnostic platform is highly sensitive and specific, giving us great confidence that a high performance COVID-19 antigen test can be developed and launched commercially very quickly,” said Dr. Alastair Smith, Chief Executive Officer of Avacta Group. “We believe that the BAMS test will be hugely attractive as an adjunct to PCR testing because it uses laboratory equipment that is already in hospital labs but not currently used for COVID-19 testing so it provides incremental testing capacity.”

“I am pleased to have Avacta recognize the promise of the BAMS technology with respect to its sensitivity, accuracy and high throughput capacity. I have worked with Affimers previously and have found them to be excellent immunoassay reagents, so we are looking forward to quickly implementing the SARS-COV-2 Affimers in a BAMS diagnostic test,” said Dr. Jeffrey C. Silva, Director of Product Development, Adeptrix Corporation. “Mass spectrometry can enhance the diagnostic utility of immunoassays, as it is capable of monitoring both existing and emerging viral strains by accurately measuring the molecular components of the virus. BAMS provides an ideal multiplexing platform to obtain higher specificity for monitoring COVID-19 infection. We are excited to be working with Avacta to rapidly develop BAMS tests and supply them to clinical diagnostic laboratories.”

Related Links:
Avacta Group plc
Adeptrix